United Therapeutics Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Martine A. Rothblatt
- Full Time Employees
- 1,400
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 1040 Spring Street Silver Spring MD United States 20910
- IPO Date
- Jun 17, 1999
- CIK
- 0001082554
- Website
- unither.com
- Similar Companies
- Business
- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit biotechnology company founded in 1996 and headquartered in Silver Spring, Maryland, with co-headquarters in Research Triangle Park, North Carolina, develops and commercializes innovative products to address unmet medical needs of patients with chronic and life-threatening diseases, particularly pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), high-risk neuroblastoma, and organ failure; its core commercial portfolio includes Tyvaso DPI and Tyvaso, inhaled formulations of treprostinil via dry powder inhaler and nebulizer for PAH and other lung conditions; Remodulin (treprostinil) injection and Orenitram (treprostinil extended-release tablets) for PAH to improve exercise capacity and delay disease progression; Adcirca (tadalafil), an oral PDE-5 inhibitor for PAH; Unituxin (dinutuximab) injection, a monoclonal antibody for pediatric high-risk neuroblastoma; and Remunity Pump, a subcutaneous delivery system for Remodulin. The company operates in the United States, Canada, Central and South America, Europe, the Middle East, and Asia through distribution partners and maintains manufacturing facilities in locations including Melbourne and Jacksonville, Florida; Blacksburg, Virginia; Manchester, New Hampshire; and Magog and Bromont, Quebec. United Therapeutics targets patients with cardiovascular, pulmonary, oncology, and organ transplant needs, while advancing a pipeline featuring RemoPro and ralinepag for PAH, Aurora-GT gene therapy for lung vascular rebuilding, nebulized Tyvaso for IPF, and xenotransplantation technologies including UKidney for end-stage renal disease via xenografts, allogenic recellularization, and bioprinting. In recent developments, United Therapeutics announced the first human transplant in its EXPAND clinical trial of UKidney for end-stage renal disease in November 2025, marking a milestone in xenotransplantation; the company reported positive top-line results from the phase 3 TETON-2 pivotal study of nebulized Tyvaso in IPF in September 2025, meeting the primary endpoint and key secondary measures across subgroups; it initiated a $1 billion accelerated share repurchase program in August 2025 with Citibank to return capital to shareholders while supporting growth; and earlier acquired IVEVA and MiroMatrix to bolster organ manufacturing expertise, alongside investments in new manufacturing facilities and designated pathogen-free sites.
Company News
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock
United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD
United Therapeutics (NASDAQ:UTHR) CEO Sells $5,129,905.00 in Stock
United Therapeutics (NASDAQ:UTHR) Stock: Insider Paul Mahon Sells 8,300 Shares
2,241 United Therapeutics Corporation $UTHR Shares Sold by First Citizens Bank & Trust Co.
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Liquidia shares surge 25% as settlement ends United Therapeutics litigation
SGIOY or UTHR: Which Is the Better Value Stock Right Now?
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
Contrasting United Therapeutics (NASDAQ:UTHR) & Intellia Therapeutics (NASDAQ:NTLA)
United Therapeutics (NASDAQ:UTHR) CEO Sells $5,215,025.00 in Stock
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday